RARE ULTRAGENYX PHARMACEUTICAL INC Product Launches 8-K Filing 2024 - UX701 Study Update Ultragenyx Pharmaceutical Inc. reported positive results from its Phase 1/2/3 Cyprus2+ study of the UX701 gene therapy for Wilson disease, with 15 patients enrolled and 6 completely tapering off standard treatment, indicating meaningful clinical activity and safety.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC